Denali Therapeutics Inc.
DNLI Healthcare Biotechnology
In the quarter to June 2026, revenue fell 89.7%, EPS grew 5.56%, free cash flow fell 22.9% and total debt fell 1.76%, each against the same quarter a year earlier. Revenue growth for three consecutive years.
Follow DNLI
Denali Therapeutics Inc. (DNLI) EV/Sales
As of 16 October 2026, Denali Therapeutics Inc. (DNLI) trades at a EV/Sales of 8.6×. Over the past ten years it has ranged from 0.0× (December 2018) to 390× (December 2020); the current reading is higher than 41% of that period. That is below the Biotechnology industry median of 9.2× and above the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2023 | 5.9× | (70.70%) |
| FY2022 | 20.1× | (78.75%) |
| FY2021 | 94.8× | 312.13% |
| FY2020 | 23.0× | (53.47%) |
| FY2019 | 49.4× | 340.67% |
| FY2018 | 11.2× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 13.8× | 133.05% |
| Dec 2023 | 5.9× | 21.05% |
| Sep 2023 | 4.9× | (42.36%) |
| Jun 2023 | 8.5× | (55.02%) |
| 21 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| CELC Celcuity, Inc. compare | n/m |
| DYN Dyne Therapeutics, Inc. compare | n/m |
| ELVN Enliven Therapeutics, Inc. compare | n/m |
| NRIX Nurix Therapeutics, Inc. compare | 2.4× |
| ZLAB Zai Lab Limited Unsponsored ADR compare | 4.7× |
| DNLI Denali Therapeutics Inc. | 8.6× |
| IDYA IDEAYA Biosciences, Inc. compare | 9.4× |
| RCUS Arcus Biosciences, Inc. compare | 18.7× |
| XENE Xenon Pharmaceuticals Inc. compare | 144× |
| Biotechnology industry median | 9.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)